Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$65.50 -0.5%	$64.31	$52.50 ▼ $77.00	$1.42B	0.55	311,463 shs	325,389 shs
BBIO BridgeBio Pharma	$44.86 -0.6%	$37.11	$21.72 ▼ $45.48	$8.52B	1.1	2.48 million shs	8.45 million shs
BPMC Blueprint Medicines	$128.11 0.0%	$109.27	$73.04 ▼ $128.45	$8.27B	0.84	1.30 million shs	2.99 million shs
LEGN Legend Biotech	$34.63 +3.4%	$32.38	$27.34 ▼ $60.87	$6.36B	0.13	1.36 million shs	1.81 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-0.47%	-0.09%	+13.30%	-3.12%	+0.02%
BBIO BridgeBio Pharma	-0.58%	+7.50%	+39.06%	+27.77%	+90.41%
BPMC Blueprint Medicines	-0.03%	-0.07%	+34.43%	+44.40%	+23.28%
LEGN Legend Biotech	+3.43%	+1.85%	+22.41%	-1.23%	-22.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.5886 of 5 stars	2.5	1.0	3.3	1.7	3.3	1.3
BBIO BridgeBio Pharma	4.6787 of 5 stars	4.5	2.0	3.9	2.6	3.3	0.6
BPMC Blueprint Medicines	1.7313 of 5 stars	2.1	4.0	0.0	2.9	0.8	0.6
LEGN Legend Biotech	2.1845 of 5 stars	3.5	1.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	22.33% Upside
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.42	27.99% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.04% Downside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	120.04% Upside

Current Analyst Ratings Breakdown

Latest ANIP, BBIO, LEGN, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.31	$7.60 per share	8.62	$19.11 per share	3.43
BBIO BridgeBio Pharma	$221.90M	38.39	N/A	N/A	($7.71) per share	-5.82
BPMC Blueprint Medicines	$508.82M	16.26	N/A	N/A	$4.70 per share	27.26
LEGN Legend Biotech	$627.24M	10.15	N/A	N/A	$5.70 per share	6.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.56	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.09	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)

Latest ANIP, BBIO, LEGN, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
LEGN Legend Biotech	0.30	5.20	5.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
LEGN Legend Biotech	70.89%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
LEGN Legend Biotech	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable

ANIP, BBIO, LEGN, and BPMC Headlines

Recent News About These Companies

Legend Biotech (NASDAQ:LEGN) Trading Up 4.7% - Here's What Happened

June 27 at 12:55 PM | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Shares Down 4.9% - Should You Sell?

June 25 at 12:13 PM | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Eli Lilly & Co (LLY) and Exelixis (EXEL)

June 24, 2025 | theglobeandmail.com

E Fund Management Hong Kong Co. Ltd. Cuts Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)

June 24, 2025 | marketbeat.com

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Sold by Matthews International Capital Management LLC

June 19, 2025 | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Shares Gap Down - Here's What Happened

June 17, 2025 | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Stock Price Down 3.5% - Time to Sell?

June 16, 2025 | marketbeat.com

Legend Biotech Co. (NASDAQ:LEGN) Short Interest Update

June 15, 2025 | marketbeat.com

ABS Direct Equity Fund LLC Invests $1.12 Million in Legend Biotech Co. (NASDAQ:LEGN)

June 15, 2025 | marketbeat.com

GAMMA Investing LLC Buys 43,278 Shares of Legend Biotech Co. (NASDAQ:LEGN)

June 15, 2025 | marketbeat.com

SG Americas Securities LLC Buys 108,509 Shares of Legend Biotech Co. (NASDAQ:LEGN)

June 14, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Acquires 33,096 Shares of Legend Biotech Co. (NASDAQ:LEGN)

June 13, 2025 | marketbeat.com

Legend Biotech Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Legend Biotech Corporation (LEGN)

June 11, 2025 | accessnewswire.comA

Legend Biotech (NASDAQ:LEGN) Trading 7.6% Higher - Time to Buy?

June 10, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Legend Biotech FY2026 Earnings

June 10, 2025 | marketbeat.com

LEGN STOCK ALERT: Levi & Korsinsky Notifies Legend Biotech Corporation Investors of an Ongoing Investigation

June 10, 2025 | accessnewswire.comA

Shareholders That Lost Money on Legend Biotech Corporation (LEGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - LEGN

June 9, 2025 | accessnewswire.comA

Legend Biotech Co. (NASDAQ:LEGN) Receives Average Recommendation of "Moderate Buy" from Analysts

June 8, 2025 | marketbeat.com

Levi & Korsinsky Announces an Investigation on Behalf of Legend Biotech Corporation (LEGN) Shareholders Who May Have Been Affected by Fraud

June 6, 2025 | accessnewswire.comA

Legend Biotech (NASDAQ:LEGN) Shares Gap Up - Time to Buy?

June 5, 2025 | marketbeat.com

LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money

June 5, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, BBIO, LEGN, and BPMC Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$65.50 -0.31 (-0.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$65.46 -0.05 (-0.07%)

As of 06/27/2025 04:34 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

BridgeBio Pharma NASDAQ:BBIO

$44.86 -0.26 (-0.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$43.76 -1.11 (-2.46%)

As of 06/27/2025 07:30 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.11 -0.04 (-0.03%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$128.01 -0.10 (-0.08%)

As of 06/27/2025 07:00 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Legend Biotech NASDAQ:LEGN

$34.63 +1.15 (+3.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$35.20 +0.57 (+1.64%)

As of 06/27/2025 07:39 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time